1
|
Zhao X, Zhang R. Feasibility of 4D VMAT-CT. Biomed Phys Eng Express 2022; 8:10.1088/2057-1976/ac9848. [PMID: 36206726 PMCID: PMC9629170 DOI: 10.1088/2057-1976/ac9848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 10/07/2022] [Indexed: 11/11/2022]
Abstract
Objective.Feasibility of three-dimensional (3D) tracking of volumetric modulated arc therapy (VMAT) based on VMAT-computed tomography (VMAT-CT) has been shown previously by our group. However, 3D VMAT-CT is not suitable for treatments that involve significant target movement due to patient breathing. The goal of this study was to reconstruct four-dimensional (4D) VMAT-CT and evaluate the feasibility of tracking based on 4D VMAT-CT.Approach.Synchronized portal images of phantoms and linac log were both sorted into four phases, and VMAT-CT+ was generated in each phase by fusing reconstructed VMAT-CT and planning CT using rigid or deformable registration. Dose was calculated in each phase and was registered to the mean position planning CT for 4D dose reconstruction. Trackings based on 4D VMAT-CT+ and 4D cone beam CT (CBCT) were compared. Potential uncertainties were also evaluated.Main results.Tracking based on 4D VMAT-CT+ was accurate, could detect phantom deformation and/or change of breathing pattern, and was superior to that based on 4D CBCT. The impact of uncertainties on tracking was minimal.Significance.Our study shows it is feasible to accurately track position and dose based on 4D VMAT-CT for patients whose VMAT treatments are subject to respiratory motion. It will significantly increase the confidence of VMAT and is a clinically viable solution to daily patient positioning,in vivodosimetry and treatment monitoring.
Collapse
Affiliation(s)
- Xiaodong Zhao
- Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO, USA
| | - Rui Zhang
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA, USA
- Department of Radiation Oncology, Mary Bird Perkins Cancer Center, Baton Rouge, LA, USA
| |
Collapse
|
2
|
Atwell D, Elks J, Cahill K, Hearn N, Vignarajah D, Lagopoulos J, Min M. A Review of Modern Radiation Therapy Dose Escalation in Locally Advanced Head and Neck Cancer. Clin Oncol (R Coll Radiol) 2020; 32:330-341. [PMID: 31911016 DOI: 10.1016/j.clon.2019.12.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 10/27/2019] [Accepted: 11/07/2019] [Indexed: 12/30/2022]
Abstract
The management of head and neck cancer is complex and often involves multimodality treatment. Certain groups of patients, such as those with inoperable or advanced disease, are at higher risk of treatment failure and may therefore benefit from radiation therapy dose escalation. This can be difficult to achieve without increasing toxicity. However, the combination of modern treatment techniques and increased research into the use of functional imaging modalities that assist with target delineation allows researchers to push this boundary further. This review aims to summarise modern dose escalation trials to identify the impact on disease outcomes and explore the growing role of functional imaging modalities. Studies experimenting with dose escalation above standard fractionated regimens as outlined in National Comprehensive Cancer Network guidelines using photon therapy were chosen for review. Seventeen papers were considered suitable for inclusion in the review. Eight studies investigated nasopharyngeal cancer, with the remainder treating a range of subsites. Six studies utilised functional imaging modalities for target delineation. Doses as high as 85.9 Gy in 2.6 Gy fractions (EQD2 90.2 Gy10) were reportedly delivered with the aid of functional imaging modalities. Dose escalation in nasopharyngeal cancer resulted in 3-year locoregional control rates of 86.6-100% and overall survival of 82-95.2%. For other mucosal primary tumour sites, 3-year locoregional control reached 68.2-85.9% and 48.4-54% for overall survival. There were no clear trends in acute or late toxicity across studies, regardless of dose or addition of chemotherapy. However, small cohort sizes and short follow-up times may have resulted in under-reporting. This review highlights the future possibilities of radiation therapy dose escalation in head and neck cancer and the potential for improved target delineation with careful patient selection and the assistance of functional imaging modalities.
Collapse
Affiliation(s)
- D Atwell
- Cancer Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia; Icon Cancer Centre, Maroochydore, Queensland, Australia; Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
| | - J Elks
- Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| | - K Cahill
- Cancer Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia; Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| | - N Hearn
- Cancer Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia; Icon Cancer Centre, Maroochydore, Queensland, Australia; Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| | - D Vignarajah
- Cancer Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia; Icon Cancer Centre, Maroochydore, Queensland, Australia
| | - J Lagopoulos
- Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| | - M Min
- Cancer Services, Sunshine Coast University Hospital, Birtinya, Queensland, Australia; Icon Cancer Centre, Maroochydore, Queensland, Australia; Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Sippy Downs, Queensland, Australia
| |
Collapse
|
3
|
Abstract
Radiotherapy is a key therapeutic modality used in the treatment of oral cavity and oropharyngeal cancers, whether as definitive treatment or postoperatively for those with high-risk factors after surgery. Although radiotherapy is a proven, effective treatment of cancer control, it can result in significant acute and late toxicities. Pretreatment patient education, supportive care, and posttreatment adherence to rehabilitative and preventive care can help mitigate toxicities. Advances in radiation delivery, such as through continued technological advances, or novel approaches to customizing radiation dose and volume, to maximize the therapeutic efficacy while minimizing side effects, are warranted.
Collapse
Affiliation(s)
- Alexander Lin
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, TRC 2-West, Philadelphia, PA 19104, USA.
| |
Collapse
|
4
|
Vergalasova I, Light K, Chino J, Craciunescu O. Simultaneous integrated boost (SIB) for treatment of gynecologic carcinoma: Intensity-modulated radiation therapy (IMRT) vs volumetric-modulated arc therapy (VMAT) radiotherapy. Med Dosim 2017; 42:230-237. [DOI: 10.1016/j.meddos.2017.05.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 04/26/2017] [Accepted: 05/18/2017] [Indexed: 01/13/2023]
|
5
|
Cilla S, Deodato F, Digesù C, Macchia G, Picardi V, Ferro M, Sallustio G, De Spirito M, Piermattei A, Morganti AG. Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. Med Dosim 2013; 39:108-16. [PMID: 24342167 DOI: 10.1016/j.meddos.2013.11.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2013] [Revised: 10/02/2013] [Accepted: 11/11/2013] [Indexed: 10/25/2022]
Abstract
Intensity-modulated radiotherapy (IMRT) allowed the simultaneous delivery of different doses to different target volumes within a single fraction, an approach called simultaneous integrated boost (SIB). As consequence, the fraction dose to the boost volume can be increased while keeping low doses to the elective volumes, and the number of fractions and overall treatment time will be reduced, translating into better radiobiological effectiveness. In recent years, volumetric-modulated arc therapy (VMAT) has been shown to provide similar plan quality with respect to fixed-field IMRT but with large reduction in treatment time and monitor units (MUs) number. However, the feasibility of VMAT when used with SIB strategy has few investigations to date. We explored the potential of VMAT in a SIB strategy for complex cancer sites. A total of 15 patients were selected, including 5 head-and-neck, 5 high-risk prostate, and 5 rectal cancer cases. Both a double-arc VMAT and a 7-field IMRT plan were generated for each case using Oncentra MasterPlan treatment planning system for an Elekta Precise linac. Dosimetric indexes for targets and organs at risk (OARs) were compared based on dose-volume histograms. Conformity index, homogeneity index, and dose-contrast index were used for target analyses. The equivalent uniform doses and the normal tissue complication probabilities were calculated for main OARs. MUs number and treatment time were analyzed to score treatment efficiency. Pretreatment dosimetry was performed using 2-dimensional (2D)-array dosimeter. SIB-VMAT plans showed a high level of fluence modulation needed for SIB treatments, high conformal dose distribution, similar target coverage, and a tendency to improve OARs sparing compared with the benchmark SIB-IMRT plans. The median treatment times reduced from 13 to 20 minutes to approximately 5 minutes for all cases with SIB-VMAT, with a MUs reduction up to 22.5%. The 2D-array ion-chambers' measurements reported an agreement of more than 95% for a criterion of 3% to 3mm. SIB-VMAT was able to combine the advantages of conventional SIB-IMRT with its highly conformal dose distribution and OARs sparing and the advantages of 3D-conformal radiotherapy with its fast delivery.
Collapse
Affiliation(s)
- Savino Cilla
- Medical Physics Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy.
| | - Francesco Deodato
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Cinzia Digesù
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Gabriella Macchia
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Vincenzo Picardi
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Marica Ferro
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Giuseppina Sallustio
- Radiology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| | - Marco De Spirito
- Physics Institute, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Angelo Piermattei
- Physics Institute, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Alessio G Morganti
- Radiation Oncology Unit, Fondazione di ricerca e cura "Giovanni Paolo II," Università Cattolica del Sacro Cuore, Campobasso, Italy
| |
Collapse
|
6
|
High-Dose and Extended-Field Intensity Modulated Radiation Therapy for Early-Stage NK/T-Cell Lymphoma of Waldeyer's Ring: Dosimetric Analysis and Clinical Outcome. Int J Radiat Oncol Biol Phys 2013; 87:1086-93. [DOI: 10.1016/j.ijrobp.2013.08.040] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 08/19/2013] [Accepted: 08/27/2013] [Indexed: 11/22/2022]
|